Second Quarter 2023 Financial Results Forward-looking Non-GAAP Financial Statements Information This presentation contains forward-looking statements, which reflect the current views of We use non-GAAP*financial measures, such as adjusted net income, adjusted diluted Zoetis with respect to: business plans or prospects; future operating or financial earnings per share, adjusted operating expenses, adjusted gross margin, operational performance, future guidance, future operating models; disruptions in our glo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number:001-35797 Zoetis Inc. (Exact name of registrant as specified in its charter) Delaware 46-0696167 (State or othe ...

Financial Data and Key Metrics Changes - The company reported Q1 2023 revenue of $2 billion, growing 1% on a reported basis and 4% operationally, with adjusted net income of $607 million, declining 3% on both a reported and operational basis [14][15][28] - The operational revenue growth of 4% was driven by a 5% increase from price and a 1% decline in volume, primarily due to U.S. companion animal distributor destocking [14][15] - Adjusted gross margins were 70.8%, declining 80 basis points compared to the prior year, attributed to higher manufacturing costs and unfavorable product mix [25][26] Business Line Data and Key Metrics Changes - The livestock portfolio led growth with a 12% operational increase, while companion animal product revenues were flat operationally [6][15] - U.S. livestock sales grew 15%, driven by improved supply of key products, while companion animal products in the U.S. declined 7% [19][23] - International revenue grew 10% operationally, with both companion animal and livestock segments contributing to this growth [23][24] Market Data and Key Metrics Changes - U.S. veterinary clinic visits increased by 2%, with clinic revenue growth of 11% and average spend per visit up 9% [9][20] - Sales out of distributors to clinics were up 8% on a volume basis, and retail sales to pet owners increased by 35% [8][37] - The international livestock segment also grew 10% operationally, driven by cattle and sheep portfolios [25] Company Strategy and Development Direction - The company plans to continue investing in key product areas such as parasiticides, dermatology, monoclonal antibodies, vaccines, and diagnostics to support future growth [11][12] - A new manufacturing site outside Atlanta, Georgia, was purchased to expand capacity for monoclonal antibodies and vaccines, expected to begin operations in 2026 [12] - The company remains committed to delivering strong growth in 2023 based on market leadership and innovative franchises [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year guidance despite economic uncertainties, expecting operational growth of 6% to 8% in revenue and 7% to 9% in adjusted net income [5][29] - The company anticipates a return to growth in U.S. diagnostics and expects strong demand for innovative companion animal products [10][11] - Management noted that the first quarter results were in line with expectations and emphasized the importance of a diverse portfolio for steady growth [14][29] Other Important Information - Capital expenditures in Q1 were $223 million, with expectations for a significant increase throughout 2023 [28] - The company repurchased $283 million of shares and increased dividends by over 15% compared to Q1 2022 [28] Q&A Session Summary Question: Is the channel now normalized in the U.S.? - Management confirmed that the channel is at normalized levels and discussed the destocking dynamics that occurred in Q1, which were anticipated [32][35] Question: Was there a stocking benefit across livestock in the segment in the quarter? - Management indicated that livestock growth was driven by resupply and increased supply of key products, but expects flat growth for the year [39][40] Question: What drove the decline in the dermatology segment? - The decline was attributed to destocking from pre-price buy-ins and promotional impacts, but management expects double-digit growth for the rest of the year [41][68] Question: Any feedback from the price increases at the beginning of the year? - Management reported no pushback from veterinarians or pet owners regarding price increases, with significant growth observed in distributor sales to clinics and retail sales to pet owners [70][73]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number:001-35797 Zoetis Inc. (Exact name of registrant as specified in its charter) Delaware 46-0696167 (State or oth ...

Fourth Quarter and Full Year 2022 Financial Results Forward-looking Non-GAAP Financial Statements Information This presentation contains forward-looking statements, which reflect the current views of We use non-GAAP*financial measures, such as adjusted net income, adjusted diluted Zoetis with respect to: business plans or prospects; future operating or financial earnings per share, adjusted operating expenses, adjusted gross margin, operational performance, future guidance, future operating models; disrupti ...

Zoetis Inc. (NYSE:ZTS) Q4 2022 Earnings Conference Call February 14, 2023 8:30 AM ET Company Participants Steve Frank - Vice President, Investor Relations Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Jon Block - Stifel Erin Wright - Morgan Stanley Louise Chen - Cantor Nathan Rich - Goldman Sachs David Westenberg - Piper Sandler Chris Schott - JPMorgan Brandon Vazquez - William Blair Elliot Wilbur - Raymond James ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Zoetis Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-35797 Delaware 46-0696167 (State or other j ...

Zoetis Inc. (NYSE:ZTS) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Nathan Rich - Goldman Sachs Louise Chen - Cantor Jon Block - Stifel Brandon Vazquez - William Blair Chris Schott - JPMorgan David Westenberg - Piper Sandler Steve Scala - Cowen Michael ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-35797 Zoetis Inc. (Exact name of registrant as specified in its charter) | --- | -- ...